News
-
-
-
COMMUNIQUÉ DE PRESSE
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
Norgine's PEDMARQSI(R) registered by TGA in Australia for preventing cisplatin-induced hearing loss in children. Approval addresses significant unmet medical need in paediatric oncology -
-
-
COMMUNIQUÉ DE PRESSE
Norgine announces Swissmedic approval of PEDMARQSI® for the prevention of cisplatin induced hearing loss in children
Norgine announces Swissmedic approval of PEDMARQSI(R) for the prevention of cisplatin induced hearing loss in children. PEDMARQSI(R) becomes the first treatment in Switzerland for this medical need -
-
-
COMMUNIQUÉ DE PRESSE
Norgine welcomes positive CHMP opinion recommending approval of mavorixafor in the European Union for WHIM syndrome
Norgine's mavorixafor receives positive CHMP opinion for WHIM syndrome treatment in the EU. Final EC decision expected in Q2 2026. Partnership with X4 Pharmaceuticals
